The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Atyr Pharma Inc. Common Stock 002120103 1,006 1,827,992 SH   SOLE   1,827,992 0 0
Cardlytics, Inc. Common Stock 14161W105 42,476 2,552,626 SH   SOLE   2,552,626 0 0
Dare Bioscience, Inc. Common Stock 23666P101 457 326,243 SH   SOLE   326,243 0 0
Fate Therapeutics, Inc. Common Stock 31189P102 25,884 1,473,186 SH   SOLE   1,473,186 0 0
Genocea Biosciences, Inc. Common Stock 372427104 1,161 1,968,606 SH   SOLE   1,968,606 0 0
Kala Pharmaceuticals, Inc. Common Stock 483119103 15,362 1,857,582 SH   SOLE   1,857,582 0 0
Neuronetics, Inc. Common Stock 64131A105 11,320 742,289 SH   SOLE   742,289 0 0
Pulmatrix, Inc. Common Stock 74584P103 456 359,438 SH   SOLE   359,438 0 0
Selecta Biosciences, Inc. Common Stock 816212104 6,573 2,773,479 SH   SOLE   2,773,479 0 0
T2 Biosystems, Inc. Common Stock 89853L104 4,844 1,841,924 SH   SOLE   1,841,924 0 0
Trevena, Inc. Common Stock 89532E109 3,204 2,053,540 SH   SOLE   2,053,540 0 0
x4 Pharmaceuticals Inc Common Stock 98420x103 5,423 311,492 SH   SOLE   311,492 0 0